Explore the Agenda

8:00 am Check In & Registration

8:45 am Chair’s Opening Remarks

Designing Innovative Combination Strategies That Target Intrinsic Resistance & Pathway Crosstalk to Deliver Broader, More Durable RAS Control

9:00 am Advancing PLK1 Targeted Therapy to Transform Outcomes in RAS Mutant Metastatic Colorectal Cancer

CEO, Cardiff Oncology
  • Leveraging PLK1 based synthetic lethality to address RAS mutant metastatic colorectal cancer with a highly selective PLK-1 inhibitor, onvansertib
  • Demonstrating potentially practice changing clinical activity and tolerability of onvansertib with FOLFIRI/bev in front line RAS-mut mCRC in a randomized controlled Phase II study
  • Defining a clinical path toward approvability through ongoing first line development and combination with a standard chemotherapy backbone in an area of high unmet need with limited advancements

9:30 am Disruption of the RAS-PI3Kα Interaction Provides Enhanced Efficacy in Combination Mutant KRAS Targeting Therapies

Scientist, Vividion Therapeutics
  • Targeting oncogenic RAS-PI3Kα signaling with small molecules that selectively block the RAS-PIK3CA interaction while preserving homeostatic PI3Kα function, improving tolerability in ways traditional active site inhibitors cannot
  • Enhancing antitumor activity by combining selective RAS-PIK3CA inhibition with MAPK pathway agents, achieving dramatic efficacy improvements in preclinical RAS driven cancer models
  • Countering intrinsic & adaptive resistance to direct mutant KRAS inhibitors through blockage of WT RAS-driven activation of the PI3K/AKT pathway

10:00 am Morning Break & Networking

11:00 am Expanding Patient Reach: Developing Novel INCB161734 (KRAS G12D Inhibitors) Combinations That Work Across Heterogeneous Tumors

Associate Director, Incyte Corporation
  • Combining KRAS inhibitors with orthogonal agents in novel ways to increase the depth and breadth of efficacy in heterogenous tumors
  • Reevaluating ways to broaden, not shrink, the treatable KRAS G12D patient population, avoiding combinations that only benefit narrow biomarker defined subsets
  • Mutant-selective KRAS inhibitors enable maximal mutant KRAS inhibition while limiting off-tumor to the extent possible off-tumor activity

11:30 am Expanding the Druggable Landscape: Targeting Signalling, Cytoskeletal & Chromatin Pathways to Unlock Next-Generation RAS Combination Strategies

Professor, Georgetown University
  • Identifying novel druggable vulnerabilities across signalling, cytoskeletal, and chromatin networks to open new therapeutic opportunities beyond conventional targets
  • Targeting protein-protein interactions and defining optimal developmental treatment windows to maximize inhibitor impact while improving translational success
  • Leveraging RAC and RAS pathway biology alongside a predictive combination platform to design rational therapies, validated through pioneering brain cancer research and published studies

12:00 pm Lunch Break & Networking

Building Effective Combination Strategies Across the Complexity of RAS-Driven Cancers

1:00 pm Panel Discussion: How Do We Build Combination Strategies That Work Across KRAS Alleles, Co Mutations, & Tumor Types?

CMO, Jacobio Pharmaceuticals Inc
Vice President, Translational Research, Revolution Medicines
Associate Director, Incyte Corporation
Senior Director - Translational & Preclinical Research, Verastem. inc
Executive Director - Discovery Signalling, Eli Lilly & Co.
  • How do KRAS alleles, co‑mutations, and tumor lineage reshape dependency and escape, and what does that mean for choosing the right combination backbone?
  • Which combinations have true cross‑context potential, and which are only effective in specific molecular or tumor‑type settings?
  • How should we prioritise combinations that balance biological rationale, toxicity constraints, and real‑world feasibility across heterogeneous patient populations?

2:00 pm TRIM7 Inhibition Blocks RTK/RAS Pathway Driven Tumor Proliferation Independent of Mutation & in the Setting of KRASi Resistance

Chief Scientific Officer & Founder, KAYAK
  • KT-300 is a covalent small molecule inhibitor of the E3 ubiquitin ligase TRIM7, which is hyperactivated in RTK/RAS driven cancers, enabling broad activity across tumor types and offering a potential path beyond mutation-specific targeting strategies
  • KT-300 is active in the setting of KRAS inhibitor resistance, and may support sustained pathway suppression and improve the potential for durable responses in RAS-driven cancers
  • Combined blockade with KT-300 and upstream RAS-pathway inhibition (e.g.; anti- EGFR, KRASi, etc.) enhance anti-tumor responses, creating broad opportunities for rationale combinations

Optimizing the Translation of Combination Therapies into the Clinic by Delving into Trial Design, Toxicity & Real World Strategy

2:30 pm Advancing First Line Care for KRAS G12C positive & PD L1 negative NSCLC: Optimizing Targeted Therapy + Chemotherapy for a High-Unmet- Need Population

Clinical Research Medical Director, Amgen Inc.
  • Highlighting the distinct clinical profile and poor real world outcomes of KRAS G12C +ve / PD L1 -ve NSCLC, underscoring why this population represents a critical unmet need in first line treatment.
  • Demonstrating how a cleaner, biomarker defined trial design and a safer chemo + targeted therapy approach may avoid early immunotherapy related toxicities while preserving future treatment options
  • Exploring the role of translational research, including proteomics, transcriptomics, and longitudinal blood sampling, in understanding treatment response, resistance, and sequencing strategies across the patient journey

3:00 pm Chair’s Closing Remarks

3:15 pm End of Focus Day